(17alpha) - 17 hydroxy-11 methylene-19 norpregna-4,15-diene-20-in-3-one crystalline, solid pharmaceutical composition and process for the preparation and use of the (17alpha) -17-hydroxy compound -11-methylene-19 norpregna-4,15-diene-20-in-3-one crystalline.

摘要

"COMPOUND OF (17 () - 17-HYDROXY-11-METHYLENE-19-NORPREGNA-4, 15-DIENO-20-IN-3-ONA CRYSTALLINE, SOLID PHARMACEUTICAL COMPOSITION AND PROCESS FOR THE PREPARATION AND USE OF THE COMPOUND OF (17 () -17-HYDROXY-11-METHYLENE-19-NORPREGNA-4, 15-DIENO-20-IN-3-ONA CRYSTALLINE ". The described invention resides in the polymorphism found in the progestagenic steroidal compound (17 () - 17-hydroxy -11-methylene-19-norpregna-4, 15-diene-20-in-3-one. More particularly, the invention resides in the crystalline forms of said compound having unexpectedly favorable thermodynamic stability. These crystalline compounds, which can be suitably described with reference to spectral data, they can be advantageously employed as an active ingredient in solid pharmaceutical compositions.The crystalline compounds can be used in oral contraceptives and in hormone replacement therapy (HRT).